Amphastar Pharmaceuticals (NASDAQ:AMPH) announced its earnings results on Thursday. The company reported $0.12 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.11 by $0.01, Briefing.com reports. The company had revenue of $75.54 million during the quarter, compared to analyst estimates of $76.84 million. Amphastar Pharmaceuticals had a negative net margin of 3.39% and a positive return on equity of 2.15%. Amphastar Pharmaceuticals’s revenue was up 30.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.07 earnings per share.
Shares of NASDAQ AMPH traded up $0.88 during midday trading on Friday, hitting $21.59. The company’s stock had a trading volume of 735,306 shares, compared to its average volume of 117,925. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94. Amphastar Pharmaceuticals has a 1 year low of $14.40 and a 1 year high of $21.65. The firm has a market cap of $890.44 million, a price-to-earnings ratio of 56.82, a PEG ratio of 8.77 and a beta of 1.38.
Several brokerages have weighed in on AMPH. BidaskClub lowered shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 13th. Needham & Company LLC lowered their target price on shares of Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a research note on Friday, August 10th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Amphastar Pharmaceuticals in a research note on Friday. ValuEngine raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, August 17th. Finally, Zacks Investment Research raised shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 9th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $23.00.
TRADEMARK VIOLATION NOTICE: This article was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3928907/amphastar-pharmaceuticals-amph-announces-quarterly-earnings-results.html.
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Recommended Story: Why do company’s buyback their stock?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.